the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Share this:
Brief Title RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Official Title A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors
Principal Investigator Nanda, Rita
Brief Summary The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.
Gender All
Ages 18 Years
Enrollment 20
Accepts Healthy Volunteers No
Lead Sponsor Rexahn Pharmaceuticals, Inc.Industry
Study Design
Study Phase Phase 1/Phase 2
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Solid Tumor
Detail for Health Professional (on
More clinical trials by this PI